Moderna aims to prove it’s ‘more than a COVID company’

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 39 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 97%

Business News News

Business Business Latest News,Business Business Headlines

As COVID vaccine sales fall, Moderna releases positive results from mRNA flu vaccine, adds new development programs

As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc. MRNA, -0.53% on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases.

With the late-stage study of the flu vaccine, combined with previous results from COVID and RSV vaccines, “we are now three-for-three on advancing respiratory-disease programs to positive Phase 3 data,” Moderna Chief Executive Stephane Bancel said in a statement. “We always knew that if mRNA was going to be successful, it could be very successful across many different therapeutic areas,” Mock said, “and I think that’s what the data is showing us right now.”

Moderna’s next-generation, refrigerator-stable COVID vaccine, mRNA-1283, has now completed enrollment of its Phase 3 trial, the company said. Beyond respiratory products, Moderna is developing vaccines for cytomegalovirus, Epstein Barr virus, herpes simplex, varicella zoster, norovirus and HIV.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSİNESS

Business Business Latest News, Business Business Headlines